AU1087792A - Substituted benzofuranylpiperidine as a nootropic agent - Google Patents

Substituted benzofuranylpiperidine as a nootropic agent

Info

Publication number
AU1087792A
AU1087792A AU10877/92A AU1087792A AU1087792A AU 1087792 A AU1087792 A AU 1087792A AU 10877/92 A AU10877/92 A AU 10877/92A AU 1087792 A AU1087792 A AU 1087792A AU 1087792 A AU1087792 A AU 1087792A
Authority
AU
Australia
Prior art keywords
benzofuranylpiperidine
substituted
nootropic agent
treatment
nootropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU10877/92A
Other versions
AU655227B2 (en
Inventor
Cesare Dr. Mondadori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU1087792A publication Critical patent/AU1087792A/en
Application granted granted Critical
Publication of AU655227B2 publication Critical patent/AU655227B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: CIBA-GEIGY AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

4-(7-Bromo-5-methoxybenzofuran-2-yl)piperidine of the formula I <IMAGE> and its pharmaceutically utilisable salts can be used as pharmaceutical active ingredients for slowing down the degeneration of nerve cells associated with degenerative neurological disorders, and as nootropics for the treatment of disorders which respond to nootropic treatment.
AU10877/92A 1991-02-15 1992-02-10 Substituted benzofuranylpiperidine as a nootropic agent Ceased AU655227B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH47091 1991-02-15
CH470/91 1991-02-15

Publications (2)

Publication Number Publication Date
AU1087792A true AU1087792A (en) 1992-08-20
AU655227B2 AU655227B2 (en) 1994-12-08

Family

ID=4187740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10877/92A Ceased AU655227B2 (en) 1991-02-15 1992-02-10 Substituted benzofuranylpiperidine as a nootropic agent

Country Status (16)

Country Link
EP (1) EP0499586B1 (en)
JP (1) JPH0570352A (en)
KR (1) KR920016098A (en)
AT (1) ATE138805T1 (en)
AU (1) AU655227B2 (en)
CA (1) CA2061015A1 (en)
DE (1) DE59206442D1 (en)
DK (1) DK0499586T3 (en)
ES (1) ES2087497T3 (en)
GR (1) GR3020155T3 (en)
IE (1) IE74906B1 (en)
IL (1) IL100889A (en)
MX (1) MX9200620A (en)
NO (1) NO179358C (en)
NZ (1) NZ241608A (en)
ZA (1) ZA921091B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3595093A (en) * 1992-02-21 1993-09-13 Ciba-Geigy Ag Brofaromine as an agent for treating social phobia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856295T2 (en) * 1987-10-22 1999-06-17 Massachusetts Inst Technology TREATMENT OF PREMIUM OR LATE LUTEAL PHASE SYNDROME

Also Published As

Publication number Publication date
ATE138805T1 (en) 1996-06-15
GR3020155T3 (en) 1996-09-30
CA2061015A1 (en) 1992-08-16
AU655227B2 (en) 1994-12-08
DE59206442D1 (en) 1996-07-11
NO920591D0 (en) 1992-02-14
EP0499586A1 (en) 1992-08-19
IL100889A0 (en) 1992-11-15
IE920486A1 (en) 1992-08-26
IE74906B1 (en) 1997-08-13
NO179358C (en) 1996-09-25
KR920016098A (en) 1992-09-24
DK0499586T3 (en) 1996-06-24
NZ241608A (en) 1997-06-24
NO920591L (en) 1992-08-17
MX9200620A (en) 1992-08-01
JPH0570352A (en) 1993-03-23
IL100889A (en) 1997-03-18
EP0499586B1 (en) 1996-06-05
ES2087497T3 (en) 1996-07-16
ZA921091B (en) 1992-09-30
NO179358B (en) 1996-06-17

Similar Documents

Publication Publication Date Title
NO931056D0 (en) SULPHONAMIDO AND SULPHONAMIDOCARBONYL-PYRIDINE-2-CARBOXYLIC ACID AMIDES AND THEIR PYRIDINE-N-OXIDES, PROCEDURES FOR PREPARING THEREOF AND USING THE COMPOUNDS AS MEDICINES
GR3031492T3 (en) 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders
ES8705387A1 (en) N-Aryl-N-(4-Piperidinyl)amides and pharmaceutical compositions and methods employing such compounds.
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
GR3036816T3 (en) Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes
AU1331588A (en) Method for treatment of alcohol abuse
CA2107552A1 (en) Use of deprenyl to maintain, prevent loss, or recover nerve cell function
ZA949332B (en) Use of 1-{4-[4-aryl(or heteroaryl)-1-piperazinyl]-butyl}-1H-azole derivatives for the preparation of medicaments intended for the treatment of disorders of gastric secretion
IL113411A (en) Pharmaceutical composition for the treatment or prophylaxis of hyperglycaemias comprising moxonidine as active ingredient and process for the production of such composition
AU1087792A (en) Substituted benzofuranylpiperidine as a nootropic agent
AU8447991A (en) Antineoplastic effect potentiator and antineoplastic agent
ES2081834T3 (en) PIRROLIDIN-2-ONAS 4-METHYL AND 4-ETHL SUBSTITUTED.
AU4746993A (en) Azetidine compounds
WO2001046178A3 (en) Substituierte bisindolymaleimide
AU4872693A (en) Acylsulfonamido- and sulfonamidopyridine-2-carboxylic acid esters and their pyridine N-oxides, processes for their preparation and their use as medicaments
HUT61469A (en) Process for producing pharmaceutical composition with nervous system effects
AU4831279A (en) New compounds
CA2153570A1 (en) Pharmaceutical composition for treating nicotine dependence